Is INSM or ORKA more profitable?

Oruka Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Oruka Therapeutics' return on equity of -21.65% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Oruka Therapeutics N/A -21.65% -20.88%

Does the media prefer INSM or ORKA?

In the previous week, Oruka Therapeutics had 3 more articles in the media than Insmed. MarketBeat recorded 13 mentions for Oruka Therapeutics and 10 mentions for Insmed. Oruka Therapeutics' average media sentiment score of 1.33 beat Insmed's score of 1.00 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORKA or ROIV?

In the previous week, Roivant Sciences had 9 more articles in the media than Oruka Therapeutics. MarketBeat recorded 22 mentions for Roivant Sciences and 13 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.33 beat Roivant Sciences' score of 0.74 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 10 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ORKA or INCY more profitable?

Incyte has a net margin of 27.71% compared to Oruka Therapeutics' net margin of 0.00%. Incyte's return on equity of 29.93% beat Oruka Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -21.65% -20.88% Incyte 27.71% 29.93% 22.88%

Does the media favor ORKA or INCY?

In the previous week, Incyte had 7 more articles in the media than Oruka Therapeutics. MarketBeat recorded 20 mentions for Incyte and 13 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.33 beat Incyte's score of 1.18 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 15 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to UTHR or ORKA?

In the previous week, United Therapeutics had 20 more articles in the media than Oruka Therapeutics. MarketBeat recorded 33 mentions for United Therapeutics and 13 mentions for Oruka Therapeutics. United Therapeutics' average media sentiment score of 1.43 beat Oruka Therapeutics' score of 1.33 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 23 Very Positive mention(s) 6 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oruka Therapeutics (ORKA) Competitors

$91.34 -0.29 (-0.31%)

As of 02:28 PM Eastern

Compare

ORKA vs. INSM, ROIV, INCY, UTHR, and GMAB

Should you buy Oruka Therapeutics stock or one of its competitors? Oruka Therapeutics's main competitors and comparable companies include Insmed (INSM), Roivant Sciences (ROIV), Incyte (INCY), United Therapeutics (UTHR), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oruka Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Oruka Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Oruka Therapeutics' return on equity of -21.65% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Insmed has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Oruka Therapeutics had 3 more articles in the media than Insmed. MarketBeat recorded 13 mentions for Oruka Therapeutics and 10 mentions for Insmed. Oruka Therapeutics' average media sentiment score of 1.33 beat Insmed's score of 1.00 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed presently has a consensus price target of $205.52, suggesting a potential upside of 63.44%. Oruka Therapeutics has a consensus price target of $133.00, suggesting a potential upside of 44.07%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Insmed is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oruka Therapeutics has lower revenue, but higher earnings than Insmed. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$1.14B	24.14	-$1.28B	-$4.11	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Summary

Oruka Therapeutics beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Roivant Sciences?

Oruka Therapeutics (NASDAQ:ORKA) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Roivant Sciences had 9 more articles in the media than Oruka Therapeutics. MarketBeat recorded 22 mentions for Roivant Sciences and 13 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.33 beat Roivant Sciences' score of 0.74 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	10 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics presently has a consensus target price of $133.00, indicating a potential upside of 44.07%. Roivant Sciences has a consensus target price of $35.14, indicating a potential upside of 2.72%. Given Oruka Therapeutics' higher probable upside, equities analysts plainly believe Oruka Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Oruka Therapeutics has higher earnings, but lower revenue than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Roivant Sciences	$7.53M	3,280.28	-$299.77M	-$0.53	N/A

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oruka Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Oruka Therapeutics' return on equity of -21.65% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Oruka Therapeutics has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

Oruka Therapeutics beats Roivant Sciences on 8 of the 15 factors compared between the two stocks.

How does Oruka Therapeutics compare to Incyte?

Oruka Therapeutics (NASDAQ:ORKA) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Incyte has a net margin of 27.71% compared to Oruka Therapeutics' net margin of 0.00%. Incyte's return on equity of 29.93% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Incyte	27.71%	29.93%	22.88%

Incyte has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Incyte	$5.14B	5.07	$1.29B	$7.85	16.38

Oruka Therapeutics has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market. Comparatively, Incyte has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Oruka Therapeutics presently has a consensus target price of $133.00, indicating a potential upside of 44.07%. Incyte has a consensus target price of $123.10, indicating a potential downside of 4.28%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Oruka Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Incyte	0 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Incyte had 7 more articles in the media than Oruka Therapeutics. MarketBeat recorded 20 mentions for Incyte and 13 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.33 beat Incyte's score of 1.18 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	15 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Incyte beats Oruka Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

United Therapeutics has a net margin of 41.56% compared to Oruka Therapeutics' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Oruka Therapeutics	N/A	-21.65%	-20.88%

In the previous week, United Therapeutics had 20 more articles in the media than Oruka Therapeutics. MarketBeat recorded 33 mentions for United Therapeutics and 13 mentions for Oruka Therapeutics. United Therapeutics' average media sentiment score of 1.43 beat Oruka Therapeutics' score of 1.33 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	23 Very Positive mention(s)	6 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its stock price is 134% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.61	$1.33B	$27.95	17.54
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

United Therapeutics presently has a consensus price target of $646.00, suggesting a potential upside of 31.75%. Oruka Therapeutics has a consensus price target of $133.00, suggesting a potential upside of 44.07%. Given Oruka Therapeutics' higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

United Therapeutics beats Oruka Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Oruka Therapeutics compare to Genmab A/S?

Oruka Therapeutics (NASDAQ:ORKA) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Oruka Therapeutics has a beta of -0.34, meaning that its stock price is 134% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Oruka Therapeutics currently has a consensus price target of $133.00, suggesting a potential upside of 44.07%. Genmab A/S has a consensus price target of $39.50, suggesting a potential upside of 15.36%. Given Oruka Therapeutics' higher probable upside, research analysts plainly believe Oruka Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Oruka Therapeutics had 13 more articles in the media than Genmab A/S. MarketBeat recorded 13 mentions for Oruka Therapeutics and 0 mentions for Genmab A/S. Oruka Therapeutics' average media sentiment score of 1.33 beat Genmab A/S's score of 1.02 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Oruka Therapeutics	Positive
Genmab A/S	Positive

Genmab A/S has a net margin of 19.08% compared to Oruka Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Genmab A/S	19.08%	14.89%	7.73%

Genmab A/S has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Genmab A/S	$3.72B	5.74	$963M	$1.27	26.96

Summary

Genmab A/S beats Oruka Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Oruka Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORKA vs. The Competition

Export

Metric	Oruka Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.12B	$4.02B	$7.26B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-45.50	12.52	273.79	25.41
Price / Sales	N/A	1,362.92	676.44	124.05
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	5.50	16.29	12.87	6.16
Net Income	-$105.43M	-$22.72M	$3.48B	$349.24M
7 Day Performance	-4.37%	-1.41%	-0.27%	-1.43%
1 Month Performance	-2.61%	11.10%	6.56%	2.51%
1 Year Performance	497.92%	53.69%	25.23%	15.93%

Oruka Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORKA Oruka Therapeutics	2.8942 of 5 stars	$91.40 -0.3%	$133.00 +45.5%	+488.9%	$6.05B	N/A	N/A	N/A	Positive News Analyst Forecast Insider Trade
INSM Insmed	3.7117 of 5 stars	$125.77 +0.6%	$205.52 +63.4%	-12.8%	$27.32B	$1.14B	N/A	1,664
ROIV Roivant Sciences	2.095 of 5 stars	$36.30 -1.5%	$35.14 -3.2%	+175.9%	$26.61B	$7.53M	N/A	860	Insider Trade
INCY Incyte	3.6195 of 5 stars	$127.81 +0.5%	$123.10 -3.7%	+49.8%	$25.79B	$5.14B	16.28	2,844	Positive News Analyst Forecast
UTHR United Therapeutics	4.745 of 5 stars	$513.12 -1.5%	$646.00 +25.9%	+21.5%	$22.35B	$3.18B	18.36	1,400	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORKA) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oruka Therapeutics (ORKA) Competitors

ORKA vs. INSM, ROIV, INCY, UTHR, and GMAB

How does Oruka Therapeutics compare to Insmed?

Summary

How does Oruka Therapeutics compare to Roivant Sciences?

Summary

How does Oruka Therapeutics compare to Incyte?

Summary

How does Oruka Therapeutics compare to United Therapeutics?

Summary

How does Oruka Therapeutics compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oruka Therapeutics (ORKA) Competitors

ORKA vs. INSM, ROIV, INCY, UTHR, and GMAB

How does Oruka Therapeutics compare to Insmed?

Is INSM or ORKA more profitable?

Which has more volatility and risk, INSM or ORKA?

Do insiders & institutionals hold more shares of INSM or ORKA?

Does the media prefer INSM or ORKA?

Do analysts rate INSM or ORKA?

Which has preferable earnings & valuation, INSM or ORKA?

Summary

How does Oruka Therapeutics compare to Roivant Sciences?

Does the media favor ORKA or ROIV?

Do analysts rate ORKA or ROIV?

Which has better valuation and earnings, ORKA or ROIV?

Do institutionals & insiders believe in ORKA or ROIV?

Is ORKA or ROIV more profitable?

Which has more risk and volatility, ORKA or ROIV?

Summary

How does Oruka Therapeutics compare to Incyte?

Is ORKA or INCY more profitable?

Which has better valuation & earnings, ORKA or INCY?

Which has more risk and volatility, ORKA or INCY?

Do analysts prefer ORKA or INCY?

Does the media favor ORKA or INCY?

Do institutionals and insiders believe in ORKA or INCY?

Summary

How does Oruka Therapeutics compare to United Therapeutics?

Is UTHR or ORKA more profitable?

Does the media refer more to UTHR or ORKA?

Which has more volatility and risk, UTHR or ORKA?

Which has higher valuation and earnings, UTHR or ORKA?

Do analysts rate UTHR or ORKA?

Do institutionals & insiders have more ownership in UTHR or ORKA?

Summary

How does Oruka Therapeutics compare to Genmab A/S?

Which has more risk and volatility, ORKA or GMAB?

Do institutionals and insiders hold more shares of ORKA or GMAB?

Do analysts prefer ORKA or GMAB?

Does the media favor ORKA or GMAB?

Is ORKA or GMAB more profitable?

Which has preferable earnings and valuation, ORKA or GMAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools